for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Immunome Inc

IMNM.OQ

Latest Trade

9.27USD

Change

1.51(+19.46%)

Volume

28,138

Today's Range

7.74

 - 

9.46

52 Week Range

7.74

 - 

63.52

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.76
Open
7.77
Volume
28,138
3M AVG Volume
1.96
Today's High
9.46
Today's Low
7.74
52 Week High
63.52
52 Week Low
7.74
Shares Out (MIL)
12.10
Market Cap (MIL)
105.88
Forward P/E
-3.77
Dividend (Yield %)
--

Next Event

Q4 2021 Immunome Inc Earnings Release

Latest Developments

More

Immunome Provides Update On Investigational New Drug Application For Imm-Bcp-01 For Treatment Of Covid-19

Immunome Announces Submission Of An IND Application For IMM-BCP-01 For The Treatment Of COVID-19

Immunome Reports Qtrly Loss Per Share Of $0.65

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Immunome Inc

Immunome, Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company's primary focus areas are oncology and infectious diseases. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. IMM-ONC-01, is its lead oncology program, which is focused on IL-38. IMM-BCP-01, is its lead infectious disease discovery program with a focus on SARS-CoV-2, the virus that causes COVID-19. The Company is developing an antibody cocktail product candidate by identifying a combination of anti-viral antibodies produced by B cells from COVID-19 super-responders.

Industry

Biotechnology & Drugs

Contact Info

665 STOCKTON DRIVE, SUITE 300

EXTON, PA

19341

United States

+1.610.3213700

http://immunome.com/

Executive Leadership

Michael Rapp

Independent Chairman of the Board

Purnanand D. Sarma

President, Chief Executive Officer, Director

Corleen Roche

Chief Financial Officer

Sandra G. Stoneman

Chief Legal Officer, General Counsel, Company Secretary

Dennis H. Giesing

Chief Development Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-5.260

2021(E)

-2.320
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.93
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.03
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-68.22
Return on Equity (TTM)
-56.16

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up